CARDIOVASCULAR MEDICINE

Use of statins in the secondary prevention of coronary heart disease: is treatment equitable?

F D A Reid, D G Cook and P H Whincup

Department of Public Health Sciences, St George's Hospital Medical School, London SW17, UK

Correspondence to:
Correspondence to:
Fiona Reid, Department of Public Health Sciences, St George's Hospital Medical School, Cranmer Terrace, London SW17 0RE, UK;
freid{at}sghms.ac.uk

Objective: To investigate possible inequities in the use of statins for people with coronary heart disease according to a wide range of social and clinical factors.

Design and setting: Cross sectional analysis of data from the Health Survey for England 1998, a population based survey.

Subjects: 760 adults with coronary heart disease.

Results: Only 19.9% of subjects with coronary heart disease were receiving lipid lowering drugs (151 of 760; 95% confidence interval (CI) 17.0% to 22.7%). The likelihood of receiving statins was greatly reduced for older age groups: compared with those aged less than 65 years, the odds of receiving statin treatment were 0.53 (95% CI 0.35 to 0.80) for subjects aged 65–74 years, and 0.11 (95% CI 0.06 to 0.21) for subjects aged 75 years and over. Statins were given less often to current cigarette smokers than to non-smokers (odds ratio 0.55, 95% CI 0.32 to 0.96), and to subjects with angina compared with those with a previous myocardial infarct (odds ratio 0.63, 95% CI 0.43 to 0.93). Lower levels of statin use were also seen with increasing time since diagnosis (p = 0.12). No clear associations were observed with social measures.

Conclusions: Important inequalities were found in the use of statins among people with coronary heart disease, which could not be justified by evidence from the large statin trials. Proactive policies are required to ensure that the vast majority of (if not all) patients with coronary heart disease are receiving statins, regardless of age, sex, social class, smoking status, type of coronary heart disease, or time since diagnosis.

Keywords: statins; rationing; coronary heart disease; secondary prevention

Abbreviations: HDL, high density lipoprotein; LDL, low density lipoprotein; SMAC, Standing Medical Advisory Committee

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• DeWilde, S, Carey, I M, Richards, N, Whincup, P H, Cook, D G (2008). Trends in secondary prevention of ischaemic heart disease in the UK 1994 2005: use of individual and combination treatment. Heart 94: 83-88 [Abstract] [Full Text]  
• Hu, C., Dandapat, A., Chen, J., Fujita, Y., Inoue, N., Kawase, Y., Jishage, K.-i., Suzuki, H., Sawamura, T., Mehta, J. L. (2007). LOX-1 deletion alters signals of myocardial remodeling immediately after ischemia-reperfusion. Cardiovasc Res 76: 292-302 [Abstract] [Full Text]  
• Gnavi, R., Migliardi, A., Demaria, M., Petrelli, A., Caprioglio, A., Costa, G. (2007). Statins prescribing for the secondary prevention of ischaemic heart disease in Torino, Italy. A case of ageism and social inequalities. Eur J Public Health 17: 492-496 [Abstract] [Full Text]  
• Ramsay, S. E., Whincup, P. H., Wannamethee, S. G., Papacosta, O., Lennon, L., Thomas, M. C., Morris, R. W. (2007). Missed opportunities for secondary prevention of cerebrovascular disease in elderly British men from 1999 to 2005: a population-based study. J Public Health (Oxf) 29: 251-257 [Abstract] [Full Text]  
• Bonovas, S., Filioussi, K., Flordellis, C. S., Sitaras, N. M. (2007). Statins and the Risk of Colorectal Cancer: A Meta-Analysis of 18 Studies Involving More Than 1.5 Million Patients. JCO 25: 3462-3468 [Abstract] [Full Text]  
• Ashworth, M., Lloyd, D., Smith, R. S., Wagner, A., Rowlands, G. (2007). Social deprivation and statin prescribing: a cross-sectional analysis using data from the new UK general practitioner 'Quality and Outcomes Framework'. J Public Health (Oxf) 29: 40-47 [Abstract] [Full Text]  
• Harries, C., Forrest, D., Harvey, N., McClelland, A., Bowling, A. (2007). Which doctors are influenced by a patient's age? A multi-method study of angina treatment in general practice, cardiology and gerontology. Qual Saf Health Care 16: 23-27 [Abstract] [Full Text]  
• de Lusignan, S., Belsey, J., Hague, N., Dhoul, N., van Vlymen, J. (2006). Audit-based education to reduce suboptimal management of cholesterol in primary care: a before and after study. J Public Health (Oxf) 28: 361-369 [Abstract] [Full Text]  
• DeWilde, S, Carey, I M, Emmas, C, Richards, N, Cook, D G (2006). Trends in the prevalence of diagnosed atrial fibrillation, its treatment with anticoagulation and predictors of such treatment in UK primary care. Heart 92: 1064-1070 [Abstract] [Full Text]  
• Murphy, N F, Simpson, C R, MacIntyre, K, McAlister, F A, Chalmers, J, McMurray, J J V (2006). Prevalence, incidence, primary care burden and medical treatment of angina in Scotland: age, sex and socioeconomic disparities: a population-based study. Heart 92: 1047-1054 [Abstract] [Full Text]  
• Byrne, M., Murphy, A. W, Walsh, J. C, Shryane, E., McGroarty, M., Kelleher, C. C (2006). A cross-sectional study of secondary cardiac care in general practice: impact of personal and practice characteristics. Fam Pract 23: 295-302 [Abstract] [Full Text]  
• Ramsay, S. E., Morris, R. W., Papacosta, O., Lennon, L. T., Thomas, M. C., Whincup, P. H. (2005). Secondary prevention of coronary heart disease in older British men: extent of inequalities before and after implementation of the National Service Framework. J Public Health (Oxf) 27: 338-343 [Abstract] [Full Text]  
• Ward, P. R, Noyce, P. R, St Leger, A. S (2005). Multivariate regression analysis of associations between general practitioner prescribing rates for coronary heart disease drugs and healthcare needs indicators. J. Epidemiol. Community Health 59: 86-86 [Full Text]  
• Chen, K., Chen, J., Li, D., Zhang, X., Mehta, J. L. (2004). Angiotensin II Regulation of Collagen Type I Expression in Cardiac Fibroblasts: Modulation by PPAR-{gamma} Ligand Pioglitazone. Hypertension 44: 655-661 [Abstract] [Full Text]  
• McLeod, A.L., Brooks, L., Taylor, V., Currie, P.F., Dewhurst, N.G. (2004). Secondary prevention for coronary artery disease. QJM 97: 127-131 [Abstract] [Full Text]  
• Ward, P R, Noyce, P R, St Leger, A S (2004). Are GP practice prescribing rates for coronary heart disease drugs equitable? A cross sectional analysis in four primary care trusts in England. J. Epidemiol. Community Health 58: 89-96 [Abstract] [Full Text]  
• Brophy, J. M., Bourgault, C., Brassard, P. (2003). The use of cholesterol-lowering medications after coronary revascularization. CMAJ 169: 1153-1157 [Abstract] [Full Text]  
• Muir, M. (2003). Hygieia. J. Epidemiol. Community Health 57: 915-916 [Full Text]  
• DeWilde, S, Carey, I M, Bremner, S A, Richards, N, Hilton, S R, Cook, D G (2003). Evolution of statin prescribing 1994-2001: a case of agism but not of sexism?. Heart 89: 417-421 [Abstract] [Full Text]  
• Bartlett, C, Davey, P, Dieppe, P, Doyal, L, Ebrahim, S, Egger, M (2003). Women, older persons, and ethnic minorities: factors associated with their inclusion in randomised trials of statins 1990 to 2001. Heart 89: 327-328 [Full Text]  
• Isles, C G (2002). Patients with acute coronary syndrome should start a statin while still in hospital. Heart 88: 5-6 [Full Text]